Toward more efficient clinical trials for amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 3, 2010, Pages 259-265

  Cudkowicz, Merit E ^a   Katz, Jon ^b   Moore, Dan H ^b   O'Neill, Gilmore ^c   Glass, Jonathan D ^d   Mitsumoto, Hiroshi ^e   Appel, Stanley ^f   Ravina, Bernard ^g   Kieburtz, Karl ^g   Shoulson, Ira ^g   Kaufmann, Petra ^e   Khan, Jaffar ^d   Simpson, Ericka ^f   Shefner, Jeremy ^h   Levin, Bruce ^e   Cwik, Valerie ⁱ   Schoenfeld, David ^a   Aggarwal, Swati ^a   McDermott, Michael P ^g   Miller, Robert G ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c BIOGEN   (United States)

^d EMORY UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f HOUSTON METHODIST HOSPITAL   (United States)

^g UNIVERSITY OF ROCHESTER   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ Muscular Dystrophy Association   (United States)

Author keywords

Amyotrophic lateral sclerosis; Network; Phase II; Therapy development

Indexed keywords

BIOLOGICAL MARKER; LITHIUM; MINOCYCLINE; PLACEBO;

AMYOTROPHIC LATERAL SCLEROSIS; BAYES THEOREM; BIOLOGICAL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; DATA BASE; DECISION MAKING; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FUNDING; HUMAN; METHODOLOGY; NULL HYPOTHESIS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROBABILITY; RESEARCH SUBJECT; REVIEW; SAMPLE SIZE; STATISTICAL DISTRIBUTION; SYSTEMATIC ERROR;

AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; RILUZOLE; TREATMENT OUTCOME;

EID: 77952190999     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903358865     Document Type: Review

References (22)

1. Ravina B, Fagan S, Hart R, Hovinga C, Murphy D, Dawson T, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003; 60:1234-9.
2. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nature. 2003; 2:566-80.
3. Welch E, Barton E, Zhuo J, Tomizawa Y, Friesen W, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007; 447:87-93.
4. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. Neurobiol Dis. 2007; 27:27-68.
5. Mathisa C, Loprestia B, Klunk W. Impact of amyloid imaging on drug development in Alzheimer's disease. Nuclear Medicine and Biology. 2007; 34:809-22.
6. Cudkowicz M, Shefner J, Simpson E, Grasso D, Yu H, Zhang H, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in ALS. Muscle and Nerve. 2008; 38:837-44.
7. Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics. 1979; 35:775-83.
8. The NINDS NET-PD Investigators. A randomized, doubleblind, futility clinical trial of creatine and minocycline in early Parkinson's disease. Neurology. 2006; 66:664-71.
9. The NINDS NET PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson's disease. Neurology. 2007; 68:20-8.
10. Gordon P, Cheung Y, Levin B, Andrews H, Doorish C, Macarthur R, et al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph Lateral Scler. 2008; 9:212-22.
11. Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006; 66:660-3.
12. Schoenfeld DA, Cudkowicz M. Design of phase II ALS clinical trials. Amyotroph Lateral Scler. 2008; 9:16-23.
13. Whitehead J. The Design and Analysis of Sequential Clinical Trials. 2nd edn. New York: John Wiley and Sons; 1997.
14. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurology. 2007; 6:1045-53.
15. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007; 69:776-84.
16. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: Wiley; 2004.
17. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca M, et al. Lithium delays progression of amyotrophic lateral sclerosis. PNAS. 2008; 105:2052-7.
18. Qureshi M, Schoenfeld D, Paliwal Y, Shui A, Cudkowicz M. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009; in press.
19. Cudkowicz M, Shefner J, Schoenfeld D, Zhang H, Andreasson K, Rothstein J, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology. 2006; 60:22-31.
20. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al., NEALS. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology. 2004; 63:1656-61.
21. Sorenson E, Windbank A, Mandrekar J, Bamlet W, Appel S, Armon C, et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008; 71:1770-5.
22. Pocock S. Clinical Trials: a Practical Approach. Chichester: John Wiley and Sons; 1983.